| __timestamp | Bausch Health Companies Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 22732000 |
| Thursday, January 1, 2015 | 2645000000 | 29245000 |
| Friday, January 1, 2016 | 2611000000 | 33206000 |
| Sunday, January 1, 2017 | 2548000000 | 31152000 |
| Monday, January 1, 2018 | 2351000000 | 10136000 |
| Tuesday, January 1, 2019 | 2350000000 | 45546000 |
| Wednesday, January 1, 2020 | 2249000000 | 43367000 |
| Friday, January 1, 2021 | 2394000000 | 81413000 |
| Saturday, January 1, 2022 | 2364000000 | 139304000 |
| Sunday, January 1, 2023 | 2559000000 | 192361000 |
| Monday, January 1, 2024 | 159417000 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding cost dynamics is crucial. Over the past decade, Bausch Health Companies Inc. and Halozyme Therapeutics, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Bausch Health's cost of revenue has remained relatively stable, averaging around $2.4 billion annually, with a slight increase of approximately 13% by 2023. In contrast, Halozyme Therapeutics has experienced a dramatic rise, with costs surging by over 740% from 2014 to 2023. This stark difference highlights the diverse strategies and market conditions faced by these companies. While Bausch Health maintains a steady course, Halozyme's growth trajectory suggests aggressive expansion and investment. As the pharmaceutical sector continues to innovate, these trends offer valuable insights into the financial strategies shaping the industry's future.
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Bausch Health Companies Inc.
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Amgen Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Sanofi vs Bausch Health Companies Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Bausch Health Companies Inc.